Cancer cells can use a variety of metabolic substrates to fulfill the bioenergetic and biosynthetic needs of their oncogenic program. Besides bioenergetics, cancer cell metabolism also directly influences genetic, epigenetic and signaling events associated with tumor progression. Many cancer cells are addicted to glutamine, and this addiction is observed in oxidative as well as in glycolytic cells. Although both oxidative and bioreductive glutamine metabolism can contribute to cancer progression and glutamine can further serve to generate peptides (including glutathione) and proteins, we report that glutamine promotes the proliferation of cancer cells independently of its use as a metabolic fuel or as a precursor of glutathione. Extracellular glutamine activates transcription factor signal transducer and activator of transcription 3 (STAT3), which is necessary and sufficient to mediate the proliferative effects of glutamine on glycolytic and oxidative cancer cells. Glutamine also activates transcription factors hypoxiainducible factor-1, mammalian target of rapamycin and c-Myc, but these factors do not mediate the effects of glutamine on cancer cell proliferation. Our findings shed a new light on the anticancer effects of L-asparaginase that possesses glutaminase activity and converts glutamine into glutamate extracellularly. Conversely, cancer resistance to treatments that block glutamine metabolism could arise from glutamine-independent STAT3 reactivation.
INTRODUCTION
Cancer cells can use a variety of metabolic substrates, including glucose, lactate and glutamine, to fuel cataplerotic pathways that ultimately produce adenosine triphosphate (ATP) and anaplerotic pathways for the biosynthesis of cell constituents. 1 When fully processed through glycolysis, glucose generates ATP, nicotinamide adenine dinucleotide (NADH), pyruvate and water. Pyruvate can be imported in mitochondria where it is catabolized to generate guanosine-5'-triphosphate and electron donors (NADH and FADH 2 ) that fuel oxidative phosphorylation (OXPHOS) for ATP generation at the electron transport chain. Reducing equivalents of cytosolic NADH can also be transferred to mitochondria (malate-aspartate shuttle) to fuel OXPHOS. Alternatively, several glycolytic intermediates and pyruvate are used for biosynthesis. For example, glucose-6-phosphate can aliment the pentose phosphate pathway for nucleotide synthesis and nicotinamide adenine dinucleotide phosphate (NADPH) production for lipogenesis; 2 3-phosphoglycerate can fuel the serine pathway for protein and nucleotide synthesis; 3 and pyruvate can generate alanine in the cytosol and citrate in mitochondria, from where citrate can be exported for lipogenesis. 4 In populations of cancer cells producing most energy through glycolysis, either because of microenvironmental influences such as hypoxia or because they are actively proliferating, glycolysis can also be coupled to lactic fermentation. 4 Lactate is released from glycolytic cells in a process facilitated by monocarboxylate transporters (MCTs), primarily MCT4. 5, 6 It can be recycled by oxidative cancer cells that express inward lactate transporters, essentially MCT1, and lactate dehydrogenase B that catalyzes the oxidation of lactate and NAD + to pyruvate, NADH and H + . 7, 8 Thus, pyruvate derived from lactate can be used to generate ATP, alanine and citrate, thereby contributing to cataplerosis and anaplerosis.
Different functions have also been identified for glutamine, and many cancer cell lines are addicted to glutamine. 9 Glutamine from liver origin is taken up by cancer cells in a process mainly facilitated by ASC amino-acid transporter 2 (SLC1A5/ASCT2). 10 Glutamine can be directly used to generate peptides (including glutathione) and proteins, serve for amino-acid exchange through the plasma membrane, or be further processed. Its metabolism, glutaminolysis, involves a two-step conversion: glutaminases convert glutamine to glutamate (deamidation), 11 and glutamate dehydrogenases (GDHs) further convert glutamate to 2-oxoglutarate (deamination). 12 Transamination reactions, during which glutamate donates a nitrogen group to generate other amino acids, also generate 2-oxoglutarate. 13 In cataplerotic reactions in mitochondria, 2-oxoglutarate oxidation yields malate, guanosine-5'-triphosphate, NADH and FADH 2 . 14 Alternatively, 2oxoglutarate can also fuel bioreductive anaplerotic reactions in the cytosol, which generate citrate for lipid biosynthesis. 15 In addition to cataplerotic and anaplerotic metabolism, many metabolic intermediates and several metabolic enzymes can be involved in oncogenic signaling. Signaling pathways modulated by metabolic intermediates are numerous. Modulations can involve posttranslational protein modifications, 16 epigenetic regulation, 16, 17 non-covalent enzyme/transporter modulation, 18 as well as direct binding to receptors. [19] [20] [21] Metabolic enzymes can also directly affect cell signaling and the transcription machinery, as recently reviewed by Lincet and Icard. 22 links exist between metabolic and signaling pathways in cancer cells, and metabolic influences on cell signaling can promote tumor aggressiveness.
In this context, although glutamine metabolism has already been intensively studied in cancer, little is known about direct influences that glutamine could exert as a signaling agent. As many cancer cell lines are addicted to glutamine independently of their basal metabolic phenotype (glycolytic versus oxidative), 23 this study addressed the possibility of a modulation of oncogenic transcription factors by glutamine. We report that glutamine per se activates signal transducer and activator of transcription 3 (STAT3), which promotes cancer cell proliferation.
RESULTS

Glutamine promotes the proliferation of glycolytic and oxidative cancer cells independently of glutaminolysis
To study the addiction of cancer cells to glutamine, we used human cancer cell lines representing metabolic archetypes. In good agreement with previous characterization, 7, 8, [24] [25] [26] in vitro measurements of cellular oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) confirmed that SiHa human cervix cancer cells have a more oxidative basal metabolism (high OCR and low ECAR) than HeLa human cervix cancer cells (intermediate OCR and ECAR), whereas MDA-MB-231 human breast cancer cells were comparatively more glycolytic (low OCR and high ECAR) ( Figure 1a ). Glutamine deprivation reduced intracellular glutamine concentration in all three cell lines, independently of the presence of serum (Supplementary Figure S1a ). Irrespectively of their basal metabolic phenotype, glutamine deprivation also reduced basal OCR (Figure 1b ) and the glycolytic efficiency ( Figure 1c ) of all three cell lines. Reduced glycolytic efficiency was due to a simultaneous decrease in glucose uptake and lactate release ( Figure 1d ). The general depression of oxidative and glycolytic metabolism resulted in a lower capability of the cells to produce ATP ( Figure 1e ). Glutamine deprivation also strongly reduced their proliferation rate (Ki-67 staining, Figure 1f ), rendering the cells almost totally unable to replicate ( Figure 1g ). Cell proliferation was totally restored when supplying ⩾ 1 mM of glutamine. Of note, glutamine deprivation did not trigger cell death, which was evidenced by unaltered caspase-3 activation and poly (ADP-ribose) polymerase cleavage (Supplementary Figure S1b) .
To try to rescue the metabolism and proliferation of glutaminedeprived cancer cells, we provided either glutamate or 2-oxoglutarate, the first two intermediates of glutaminolysis. [11] [12] [13] To avoid possible transport limitations, cell-permeable precursors dimethyl-glutamate (DM-glutamate, previously shown to regenerate intracellular stores of glutamate and glutathione) 27 and dimethyl-2-oxoglutarate (DM-2-oxoglutarate). When used at a concentration of 7 mM, the two compounds did not regenerate glutamine (Supplementary Figure S2a ) but replenished the intracellular pool of glutamate (Supplementary Figure S2b) , a downstream intermediate of glutamine metabolism and a known precursor of 2-oxoglutarate, citrate, succinate and fumarate in glutamine-deprived cancer cells. 28, 29 When used at a lower 2 mM concentration, DM-glutamate and DM-2-oxoglutarate restored the OCR (Figure 2a ) and ATP production ( Figure 2b ) of glutamine-deprived MDA-MB-231 cells. However, they did not restore these parameters in HeLa and SiHa cells (Figures 2a and b) , and glycolysis was still depressed in MDA-MB-231 cells (Supplementary Figure S2c ). Neither DM-glutamate nor DM-2oxoglutarate were capable of restoring the proliferation of glutamine-deprived cells (Figures 2c and d) , even when the compounds were used at a 7 mM concentration (Supplementary Figure S2d ). The ability of L-glutamine to support cancer cell proliferation was not shared by D-glutamine (Figure 2e and Supplementary Figure S2e ). Furthermore, in the presence of glutamine, the use of L-asparaginase, which converts L-glutamine to L-glutamate extracellularly, 30, 31 fully recapitulated the antiproliferative effects of glutamine deprivation at a dose of 1 IU/ml ( Figure 2f ). Together, these data indicated that glutamine can promote cancer cell proliferation independently of its use in oxidative and reductive glutaminolysis.
In addition of being a metabolic fuel, glutamine via glutamate is a precursor of glutathione, a major endogenous antioxidant in cells. However, supplying exogenous glutathione to glutaminedeprived cancer cells 27 did not restore their proliferation rate (Supplementary Figure S2f) and only marginally improved cell number (Supplementary Figure S2g ). Glutamine also fuels the hexosamine pathway, producing N-acetyl-glucosamine for posttranslational protein O-glycosyslation. However, providing N-acetyl-glucosamine under glutamine deprivation 32 did not restore cell proliferation (Supplementary Figure S2h) .
Altogether, these first sets of data indicated that none of the major metabolic pathways of glutamine account for its ability to promote cancer cell proliferation. We therefore envisioned that glutamine could act as a signaling agent/modulator to support cancer cell proliferation.
Glutamine independently sustains basal HIF-1 activity and cancer cell proliferation
As glutamine restriction was associated with reduced glycolysis (Figures 1c and d ) and glycolysis is important for cell proliferation, 26, 33 we focused on transcription factor hypoxiainducible factor-1 (HIF-1) that controls the expression of most glycolytic enzymes and transporters. 4, 34 HIF-1 is active as a dimer composed of HIF-1α and HIF-1β. Although HIF-1β expression is constitutive, HIF-1α expression is finely tuned by transcriptional and posttranscriptional mechanisms. 34 We found that glutamine deprivation reduced HIF-1α gene transcription in MDA-MB-231, HeLa and SiHa cancer cells (Figure 3a ), which resulted in reduced HIF-1α expression ( Figure 3b ) and reduced HIF-1 activity (HRE-luciferase reporter assay shown in Figure 3c , where the time-dependent increase in basal HIF-1 activity probably results from hypoxia in the unstirred culture of oxidative HeLa cells). 35 Glutamine deprivation reduced the transcription ( Figure 3d ) and protein expression ( Figure 3b ) of HIF-1 target MCT4 5 in the three cell lines. Comparatively, despite increased transcription (Supplementary Figure S3a ), the expression of MCT1, which is not under the control of HIF-1, 5 was not significantly altered ( Figure 3b ).
To test a causal link between basal HIF-1 activity and glutaminedependent cancer cell proliferation, we silenced HIF-1α (siHIF-1α) in our model cell lines (target extinction is shown in Supplementary Figure S3b ). Cell proliferation was not affected by siHIF-1α in the presence or absence of glutamine ( Figure 3e ). These data thus indicated that glutamine exerts independent influences on the proliferation and basal HIF-1 activity of glycolytic and oxidative cancer cells.
That HIF-1 does not control glutamine-dependent cell proliferation was further documented with DM-2-oxoglutarate, which, contrary to endogenous 2-oxoglutarate, activates HIF-1 because it generates high levels of succinate that inhibits HIF prolylhydroxylases (PHDs). 36 As expected, DM-2-oxoglutarate inhibited HIF-1 PHDs (ODD-luciferase reporter, Supplementary Figure S3c ), restored HIF-1α protein expression ( Figure 3b ), the transcriptional activity of HIF-1 (Supplementary Figure S3d ) and MCT4 expression ( Figure 3b ) in our three model cell lines. However, it did not restore cancer cell proliferation upon glutamine deprivation (Figures 2c and  d) . Thus, in our experimental conditions, cancer cell proliferation was controlled by glutamine independently of HIF-1.
Glutamine deprivation deregulates several oncogenic pathways in cancer cells
To identify the molecular pathway(s) responsible for the proliferative effects of glutamine, we extended our investigation to several oncogenic pathways known to regulate cancer cell proliferation. We included mammalian target of rapamycin (mTOR) and STAT3 that were previously reported to be under the influence of glutamine: glutamine can activate mTOR through (c) Glycolytic efficiency calculated as the ratio between lactate production and glucose consumption (**Po 0.01, ***P o0.005; n = 3 for MDA-MB-231 and SiHa: n = 4 for HeLa). (d) Glucose consumption (plain lines) and lactate production (dotted lines) measured using a CMA600 enzymatic analyzer (**P o0.01, ***P o0.005 when analyzing glucose consumption; ## P o0.01, ### Po 0.005 when analyzing lactate production; n = 4). (e) Intracellular ATP content measured using a CellTiter-Glo luminescent assay in MDA-MB-231 (n = 4), HeLa (n = 8) and SiHa (n = 4) cells (**P o0.01, ***P o0.005). (f) Cell proliferation measured using Ki-67 staining (**P o0.01, ***P o0.005; n = 6). (g) Cell number assessed using a SpectraMax i3 multi-mode microplate reader after treatment with the indicated doses of glutamine (*Po 0.05, ***Po0.005 compared with media +Q, ### Po 0.005 compared with media -Q; n = 4). (a-g) All quantitative data show means ± s.e.m.
Glutamine activates STAT3 in proliferating cancer cells phosphorylation on S2448, 37 and mTOR can in turn activate STAT3 by phosphorylation on S727 38 (human sequences). Here, western blot analysis revealed that, after 72 h of glutamine starvation, the activities of extracellular signal-regulated kinases (phospho-p42/44 on total p42/44), Src (phospho-Y416-Src/Src), p38 (phospho-T180/Y182-p38/p38) and AMP-activated protein kinase (AMPK) (phospho-T172-AMPK/AMPK) were only minimally affected ( Figure 4a ). mTOR phosphorylation on S2448 (phospho-S2448-mTOR/mTOR) was significantly decreased 48 h after glutamine depletion in MDA-MB-231, but not in HeLa and SiHa cells (Figures 4a and b) . Consistently, the phosphorylation of mTOR target p70S6K (phospho-T389-p70S6K/p70S6K) decreased only in MDA-MB-231 cells (Supplementary Figure S4a ). c-Myc expression was significantly and sustainably decreased in MDA-MB-231 and HeLa, but not in SiHa cells (Figures 4a and c) . Comparatively, STAT3 activity (phospho-Y705-STAT3/STAT3, but not phospho-S727-STAT3/STAT3) was highly significantly decreased at all time points in the three cell lines (Figures 4a and d ).
STAT3 activation by glutamine controls cancer cell proliferation
To determine which of these oncogenic pathways controls glutamine-dependent cancer cell proliferation, we targeted mTOR, c-Myc and STAT3 with specific inhibitors and/or small interfering RNAs (siRNAs). Inhibition efficiencies in MDA-MB-231, HeLa and SiHa cells are shown in Supplementary Figures S4a-d . mTOR inhibition with rapamycin or AZD8055 39 did not influence the proliferation rate of the cells cultured in the presence of glutamine (Figure 5a ). Silencing c-Myc did not affect the proliferation rate of MDA-MB-231 cells (Figure 5b ). However, sic-Myc significantly reduced HeLa and SiHa cell proliferation, albeit to the same extent in the presence of glutamine or not. Thus, at the time points that we analyzed, c-Myc and glutamine independently supported cancer cell proliferation. Comparatively, in the presence of glutamine, silencing STAT3 with SmartPool siRNAs (siSTAT3) markedly repressed the proliferation rate of all three cells lines, and the effect was strikingly similar to that seen upon glutamine removal (Figure 5c ). Importantly, siSTAT3 exerted no additional antiproliferative effect on the cells when they were glutaminedeprived. Similar to siSTAT3, STAT3 inhibitor Stattic, a specific inhibitor of STAT3 Y705 phosphorylation 40 (Supplementary Figure S4d ), blocked the proliferation of all three cell lines in the presence of glutamine ( Figure 5d ). It did so as efficiently as glutamine removal at doses ⩾ 2 μM. These experiments thus unraveled STAT3 as a potential mediator of the effects of glutamine on cancer cells.
Glutamine activates STAT3 to control cancer cell metabolism and proliferation Based on our previous observations, we sought to functionally link glutamine-induced STAT3 activation (Y705 phosphorylation) and cancer cell proliferation. For that aim, we first used epithelial growth factor (EGF), a well-known inducer of STAT3 Y705 phosphorylation 41 that did not modify STAT3 S727 phosphorylation in our model cell lines ( Supplementary Figures S5a and b ).
In the presence of glutamine, EGF did not increase the proliferation rate of MDA-MB-231, HeLa and SiHa cells (Supplementary Figure S5c ). However, in the absence of glutamine, EGF dose-dependently restored proliferation (Figure 6a ). It also fully restored OCR ( Figure 6b ) and glycolytic efficiency (Figure 6c ), with no additive effect of glutamine. Both glucose consumption and lactate production were restored ( Figure 6d ). Most importantly, when EGF was supplied in the absence of glutamine, targeting STAT3 with siSTAT3 or Stattic fully prevented the restoration of cell proliferation (Figure 6e and Figure S5c) . Thus, the restoration of proliferative and metabolic parameters by EGF in glutaminedeprived cancer cells was exquisitely dependent on the ability of EGF to activate STAT3 through Y705 phosphorylation.
We further verified that STAT3 activation was sufficient to restore the proliferation of glutamine-deprived cancer cells by using interleukin-6 (IL-6), a potent activator of JAK/STAT3 signaling 42 (Supplementary Figure S5d) . In the presence of glutamine, IL-6 did not increase the proliferation rate of MDA-MB-231, HeLa and SiHa cells (Figure 6f ). However, in the absence of glutamine, IL-6 restored the proliferation of all three cancer cell lines, and this effect was inhibited by Stattic. Together, our experiments demonstrated that STAT3 activation is sufficient to restore the proliferation of glutamine-deprived cancer cells.
We next tested whether intracellular glutamine metabolism could mediate the effects of STAT3 on cancer cell proliferation. To definitely exclude a contribution of extracellular glutamine, proliferation rescue experiments were repeated on the cells cultured in glutamine-deprived medium containing dialyzed serum. In these conditions, EGF (Supplementary Figure S5e) and IL-6 (Supplementary Figure S5f ) still restored cancer cell proliferation in a STAT3-dependent manner. Still, cancer cells deprived of exogenous glutamine can produce intracellular glutamine through protein degradation or de novo synthesis. 43, 44 However, neither glutaminase inhibitor BPTES (10 μM; Supplementary Figure S5g ) nor SmartPool siRNAs against GDH1 (siGDH1; Supplementary Figures S5h-i) , which have previously been functionally validated to inhibit glutamine metabolism, 28, 45 interfered with the ability of EGF and IL-6 to restore cancer cell proliferation in the absence of extracellular glutamine. In the presence of extracellular glutamine, BPTES and siGDH did not block cancer cell proliferation, further indicating that glutamine metabolism does not account for the STAT3-dependent proliferative effects of glutamine on the cancer cells that we tested.
Finally, we tested whether STAT3 also mediated the effects of glutamine on HIF-1. In the presence of glutamine, Stattic decreased the transcription of HIF-1α (Supplementary Figure S5j) and MCT4 (Supplementary Figure S5k) , which provided a . (c) HIF-1 activity was measured using a HRE-luciferase reporter in HeLa cells grown in the indicated media for the indicated times (*Po 0.05, ***Po 0.005; ns = not significant; n = 4). (d) SLC16A3/ MCT4 mRNA levels were determined using qRT-PCR after 24 h of culture (**P o0.01, ***Po 0.005; n = 8). (e) Cells were transfected with a control siRNA (siCTR) or a siRNA against HIF-1α (siHIF-1α). Assay medium was added 24 h later, and cell number was determined at the indicated times using a SpectraMax i3 multi-mode microplate reader. (***P o0.005; n = 8 for MDA-MB-231 and SiHa; n = 6 for HeLa). (a-e) All quantitative data show means ± s.e.m. functional link between STAT3 and basal HIF-1 activity in cancer cells. However, siHIF-1α did not impair the restoration of glutamine-deprived cancer cells proliferation by EGF ( Supplementary Figure S5l) . Thus, if on the one hand STAT3 can activate HIF-1, on the other hand HIF-1 is not an effector of STAT3 for the control of glutamine-dependent cancer cell proliferation.
Altogether, our data thus reveal that STAT3 mediates the effects of glutamine on cancer cell proliferation, independently of the need of glutamine to be metabolized and independently of its ability to activate HIF-1.
DISCUSSION
This study aimed to better understand why several cancer cell lines are addicted to glutamine irrespectively of their basal metabolic activities. We report that STAT3 is activated by glutamine and controls cancer cell proliferation independently of the metabolic use of glutamine. We further report that glutamine controls basal HIF-1 activity and cancer cell metabolism, with no direct incidence on cellular proliferation.
In cancer, glutamine is best characterized as a metabolic fuel and as a precursor of glutathione, 9 which has led to the general assumption that it exerts most of its protumoral activities as a cataplerotic/anaplerotic substrate (in oxidative and reductive glutaminolysis, as a nitrogen donor and as a substrate of the hexosamine pathway) and as a regulator of the intracellular redox balance (glutathione synthesis and metabolic production of NADPH). These functions of glutamine require its metabolic processing, and did indeed account for the general metabolic depression that we observed in this study using different cancer cell types with different basal metabolic activities (Figures 1 and 2) . Accordingly, cell-permeable forms of glutamate and 2-oxoglutarate, which were previously reported to effectively supply glutamate and 2-oxoglutarate intracellularly, 27, 28 could, to some extent, replace glutamine to support cancer cell metabolism and ATP production. Still, glutamine deprivation had antiproliferative effects that were not rescued by intermediate metabolites of glutamine metabolism (glutamate, 2-oxoglutarate, glutathione and N-acetyl-glucosamine). Proliferation impairment rather primarily depended on the absence of glutamine itself, more precisely on the specific decrease in extracellular L-glutamine availability (Supplementary Figure S2e) . Our further characterization of this paradigm led to the conclusion that, in our experimental conditions, glutamine metabolism does not control glutamine-dependent cancer cell proliferation.
Although glutamine can modulate the activity of several transcription factors (including HIF-1, mTOR, c-Myc and STAT3; this study and reports by Nicklin et al., 37 Yokogami et al., 38 Yang et al. 46 and Jewell et al. 47 ), we found that, among these factors, STAT3 is the only essential mediator of glutamine-dependent cancer cell proliferation. Glutamine activated STAT3 by promoting its phosphorylation on Y705, which was not only necessary for cell proliferation in the presence of glutamine, but also sufficient to restore cell proliferation with EGF and IL-6 in the absence of glutamine (Figures 6e and f and Supplementary Figures S5b and d) . Consequently, Stattic, a specific inhibitor of Y705 STAT3 phosphorylation, 40 repressed glutamine-EGF-and IL-6-dependent cancer cell proliferation. Yang et al. 46 documented that glutamine can further activate STAT3 through S727 phosphorylation in ovarian cancer cells, which we did not observe in our human breast and cervix cancer cell models. Of note, STAT3 S727 phosphorylation is under the control of mTOR, 38 which was barely affected by glutamine deprivation in our experimental models.
STAT3 Y705 phosphorylation is controlled by the EGFR and JAK-STAT pathways. 48 At least two possibilities could explain how glutamine activates STAT3. First, one can speculate that glutamine would act intracellularly to activate STAT3, either directly or indirectly following its export in exchange for leucine and other essential amino acids. However, our data argue against this possibility. Indeed, changes in glutamine uptake (use of dialyzed serum in glutamine-free medium) or in glutamine metabolism (use of BPTES, siGDH, DM-glutamate and DM-2-oxoglutarate) did not account for the proliferative effects of STAT3 activation. Thus, it is unlikely that glutamine acts intracellularly to activate STAT3 or to mediate the proliferative effects of STAT3. We therefore consider more likely a second possibility that glutamine could act as a signaling agent/modulator able to activate cell surface receptors that control STAT3. In support of such hypothesis, other metabolites have been previously identified to act on membrane receptors in cancer cells. For example, lactate can activate GPR81 in several cancer cell types, 20 glutamate binds to mGluR1 in triplenegative breast cancer cells, 49 and the presence of a yet unknown ATP receptor was proposed on colon cancer cells. 50 Interestingly, a receptor for L-glutamine, termed Grp, has been identified in bacteria and crystalized in the L-glutamine ligand-bound form. 51 No analog has been disclosed in eukaryotic cells to date, but the possibility of the existence of such receptor in cancer cells certainly deserves further investigation.
Our study does not establish a direct cause-effect relationship between metabolic and proliferation changes in a glutaminedependent context. However, our data assign a central role to STAT3 in both processes. Indeed, although glutamine starvation downregulated basal oxidative and glycolytic metabolism, STAT3 reactivation by EGF was sufficient to restore both types of metabolism (Figures 6b-d) . With respect to aerobic glycolysis, Phospho-Y705-STAT3 was previously reported to activate HIF-1, a master regulator of glycolysis in cancer, 34 via Akt and through directly binding to the HIF-1 complex in the cell nucleus. 52, 53 In addition, as previously observed in melanoma cells exposed to Figure 5 . STAT3 activation accounts for glutamine-dependent cancer cell proliferation. (a-d) MDA-MB-231, HeLa and SiHa cancer cells were cultured in complete medium containing 2 mM of L-glutamine (+Q) or not (-Q) during 72 h. Cell number was assessed using a SpectraMax i3 multi-mode microplate reader. (a) The cells were also supplemented with mTOR inhibitors rapamycin (10 nM) or AZD8055 (15 nM) (***P o0.005, compared with media +Q; ns, nonsignificant; n = 5). (b) The cells were transfected with a control siRNA (siCTR) or a siRNA against c-Myc (sic-Myc). After 24 h, medium was replaced with medium +Q or medium -Q (**Po0.01, ***Po 0.005 compared with siCTR +Q; ## P o0.01, ### P o0.005 compared with siCTR -Q; n = 8). (c) As in (b) but using SmartPool siRNAs against STAT3 (siSTAT3) (***P o0.005 compared with siCTR +Q; n = 6 for MDA-MB-231 and HeLa; n = 8 for SiHa). (d) As in (a) but using increasing doses of STAT3 inhibitor Stattic (***P o0.005 compared with siCTR +Q; n = 6 for MDA-MB-231 and SiHa; n = 5 for HeLa). (a-d) All quantitative data show means ± s.e.m. growth signaling factors, 54 we report here that, in response to glutamine, STAT3 stimulates the transcription of HIF-1α ( Supplementary Figures S5j) . STAT3 can indeed bind to and activate the promoter of the HIF-1α gene. 54 HIF-1α, however, was not needed for cancer cell proliferation in the presence of glutamine, did not act as a downstream effector of STAT3 to control cell proliferation, and HIF-1 activation by DM-2-oxoglutarate was not sufficient to restore the proliferation of glutamine-deprived cancer cells. Thus, other regulators of cell metabolism most probably collaborate to couple STAT3-dependent cancer cell proliferation with its associated bioenergetic and biosynthetic needs. Of note, STAT3 can also promote OXPHOS when Phospho-S727-STAT3 relocalizes from the cytosol to the inner mitochondrial membrane where it interacts with complexes I, II and V of the electron transport chain and with the mitochondrial permeability transition pore, thereby decreasing the production of reactive oxygen species and protecting against cytochrome c release. 55 In our experimental models, STAT3 phosphorylation on S727 was detected, but did not change with glutamine availability. This does not preclude a preferential mitochondrial localization of Phospho-S727-STAT3 in the presence of glutamine, but calls for follow-up studies to identify more precisely how STAT3 controls OXPHOS in a glutamine-dependent context.
Our findings could have a significant impact for cancer therapy. Several pharmacological strategies have indeed been developed to starve cancer cells from glutamine, including γ-L-glutamyl-p-nitroanilide that inhibits ASCT2-dependent glutamine uptake, 56 BPTES 57 that targets glutaminases, and L-asparaginase that has intrinsic glutaminase activity. 30 In particular, L-asparaginase is used for the treatment of acute lymphoblastic leukemia, and it blocked cancer cell proliferation to the same extent as glutamine deprivation (Figure 2f ). As the glutaminase activity of L-asparaginase is essential for its cytotoxic activity on leukemic cells, 58 the proliferation of which most often requires JAK-STAT3 activation, 59 our study suggests that L-asparaginase could inhibit JAK-STAT3 signaling by depleting extracellular glutamine. If confirmed experimentally, this possibility could help to stratify patients for L-asparaginase therapy. Conversely, resistance to drugs inhibiting glutamine uptake and metabolism could depend on growth factors (such as EGF), 41 cytokines (such as IL-6) 60 and mutations 61 that activate receptors responsible for STAT3 Y705 phosphorylation. As STAT3 can be constitutively activated following mutations 61 or stimulated by S727 phosphorylation downstream of the Ras-mitogen-activated protein kinase pathway, 62, 63 it would be particularly attractive to test experimentally whether targeting these pathways could increase the response of tumors to inhibitors of glutamine uptake and metabolism.
Conclusively, we report that STAT3 is activated by extracellular glutamine in cancer cells, which directly promotes their proliferation and indirectly sustains the high metabolic activities associated with proliferation. STAT3 activation is independent of glutamine metabolism. (a-f) MDA-MB-231, HeLa and SiHa cancer cells were cultured in complete medium containing 2 mM of L-glutamine (+Q) or not (-Q), and supplemented or not with the indicated amounts of epithelial grow factor (EGF), interleukin-6 (IL-6) and/or with 2 μM of STAT3 inhibitor Stattic. (a) Cell number was assessed using a SpectraMax i3 multi-mode microplate reader at 24, 48 and 72 h (*Po0.05, **P o0.001, **P o0.005 compared with media +Q; n = 6 for MDA-MB-231 and SiHa; n = 4 for HeLa). (b) Where indicated, EGF was used at a dose of 100 ng/ml. OCR was determined in a Seahorse bioenergetic analyzer (***Po 0.005 compared with media +Q; # P o0.05, ### P o0.005, compared with media -Q; ns, not significant: n = 8 for MDA-MB-231 and SiHa; n = 6 for HeLa). (c) Glycolytic efficiency calculated as the ratio between lactate production and glucose consumption (***P o0.005 compared with medium +Q; ### P o0.005 compared with medium -Q; ns, not significant; n = 4 for MDA-MB-231 and SiHa; n = 3 for HeLa). (d) Glucose consumption (plain lines) and lactate production (dotted lines) measured using a CMA600 enzymatic analyzer (***Po0.005 when analyzing glucose consumption; ### Po0.005 when analyzing lactate production; n = 4). (e) The cells were transfected with SmartPool control siRNA (siCTR) or with SmartPool siRNAs against STAT3 (siSTAT3). Media were replaced 24 h later by assay media containing the indicated treatments. Cell number was assessed over time using a SpectraMax i3 multi-mode microplate reader (***Po 0.005 compared with siCTR +Q; ns, not significant compared with siCTR -Q; n = 8). (f) Cells were treated as indicated, and cell number was assessed over time using a SpectraMax i3 multi-mode microplate reader (***Po 0.005 compared with media +Q; n = 8 for MDA-MB-231 and SiHa; n = 6 for HeLa.
(a-f) All quantitative data show means ± s.e.m.
MATERIALS AND METHODS
Cells and reagents
MDA-MB231 human mammary breast adenocarcinoma (ATCC, Manassas, VI, USA), HeLa human cervix cancer adenocarcinoma (ATCC) and SiHa human cervix squamous cell carcinoma (ATCC) cells were routinely cultured in Dulbecco's modified Eagle's medium containing 4.5 g/l of glucose and 2 mM of glutamax, and supplemented with 10% fetal bovine serum. Assay medium was Dulbecco's modified Eagle's medium without glucose, L-glutamine, phenol red, sodium pyruvate and sodium bicarbonate (D5030, Sigma-Aldrich, Diegem, Belgium), reconstituted with 10 mM glucose, 10% fetal bovine serum, and buffered at pH 7.4 with 3.7 g/l NaHCO 3 . Cells were grown at 37°C in a humidified 5% CO 2 atmosphere. Where indicated, cells were treated with L-glutamine (Invitrogen, Merelbeke, Belgium), dimethyl-L-glutamate (Sigma-Aldrich), dimethyl-2-oxoglutarate (Sigma-Aldrich), 2 mM of D-glutamine (Sigma-Aldrich), 5 mM of reduced glutathione (Merck Millipore, Overijse, Belgium), 10 nM of rapamycin (Sigma-Aldrich), 15 nM of AZD8055 (Selleckchem, Huissen, The Netherlands), 10-100 ng/ml of recombinant human EGF (PeproTech, Neuilly-sur-Seine, France), 20 ng/ml of recombinant IL-6 (Sigma-Aldrich), 1-10 μM of Stattic (Santa Cruz, Heidelberg, Germany), 10 μM of BPTES or 0.25-1 IU/ml of asparaginase (Sigma-Aldrich). Reagents were dissolved either in dimethylsulfoxide or directly in Dulbecco's modified Eagle's medium according to manufacturer's indications. When dimethylsulfoxide was used, an equal quantity was also added to control medium. All drugs and reagents were administered to adherent cells in fresh assay medium.
Metabolic measurements
OCRs and ECARs were measured using a XF Cell Mito Stress Test kit (Seahorse Bioscience-Agilent Technologies, Santa Clara, CA, USA) on a Seahorse XF96 bioenergetic analyzer. MDA-MB-231, HeLa and SiHa cells were pre-incubated for 24 h in assay medium. Experiments were performed following manufacturer's instructions. The concentration of glucose and lactate was measured in cell supernatant using specific enzymatic reactions on a CMA600 analyzer (CMA microdialysis, Kista, Sweden) following producer's instructions. ATP levels were measured using the CellTiter-Glo Luminescent Cell Viability assay from Promega (Leiden, The Netherlands) following manufacturer's instructions on cells that were grown for 24 h in assay medium containing or not L-glutamine (2 mM), dimethyl-L-glutamate (2 mM) or dimethyl-2-oxoglutarate (2 mM). All the above metabolic measurements were normalized for total protein content analyzed at the end of the experiment using the Bio-Rad Protein assay (Temse, Belgium) or the Pierce BCA Protein Assay kit (Thermo Fischer Scientific, Ghent, Belgium). The concentration of intracellular glutamine and glutamate was measured in cell lysates using the glutamine/ glutamate-Glo Assay kit (courtesy of Promega) following producer's instructions. Luminescence was measured using a SpectraMax miniMax 300 imaging cytometer (Molecular Devices, Wokingham, UK), and data were normalized for cell number.
Cell viability and proliferation
Cell number was determined over time from transmitted light images using a SpectraMax miniMax 300 imaging cytometer (Molecular Devices, Wokingham, UK). In all experiments, 5 × 10 3 cells were plated in black clear bottom 96-well Costar plates (Thermo Fischer Scientific) and treated 24 h later. Cell proliferation was determined using Ki-67 staining. Briefly, cells were cultured for 72 h in assay medium, after which they were immunostained using a mouse monoclonal antibody against Ki-67 (#556003, BD Biosciences, Erembodegem, Belgium) and a goat antimouse IgG1 secondary antibody (Alexa Fluor 488 conjugate, #A-21121, Invitrogen). Fluorescence of Ki-67-positive cells and total cell number were determined using a SpectraMax miniMax 300 imaging cytometer. Cell proliferation corresponds to the percentage of Ki-67-positive cells on total number analyzed using the SoftMax Pro 7 software (Molecular Devices).
Western blotting
Western blotting was performed as previously described. 8 Briefly, an equal amount of protein extracts were loaded on polyacrylamide gels, separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then blotted on PVDF membranes. Primary and secondary antibodies are reported in Supplementary Table S1 . Staining was revealed with Amersham Imager 600 (GE Healthcare, Diegem, Belgium). Data were analyzed using the Image J software (NIH, Bethesda, MD, USA).
Quantitative reverse transcriptase-PCR
Total RNA was isolated from cells using a Maxwell RSC instrument (Promega) following manufacturer's instructions. Quantitative reverse transcriptase-PCR was performed as previously described 64 with SYBR green on a ViiA 7417 Real-Time instrument (Life Technologies, Ghent, Belgium). Primers are reported in Supplementary Table S2. HIF-1 and PHD activity HIF-1 and PHD activities were measured using a dual luciferase kit from Promega with HRE-luciferase (plasmid #26731, Addgene, Cambridge, UK) as reporter of HIF-1 activity and ODD-luciferase (plasmid #18965, Addgene) as reporter of PHD activity. pRL Renilla luciferase (Promega) was used as internal control. Cells were co-transfected using the TransIT-2020 transfection reagent (Mirus Bio, Eke, Belgium).
RNA interference
Cells were transfected using Lipofectamine RNAiMAX (Invitrogen, Erembodegem, Belgium) following reverse transfection according to manufacturer's protocol. siRNAs targeted hHIF-1α 5′-AACUGGACACAGUGUG UUUGA-3' (siHIF-1α) or hc-Myc 5'-GAGAACAGUUGAAACACAA-3' (sic-Myc). ON-TARGETplus SmartPool siRNAs were used to silence hSTAT3 (Dharmacon, GE Healthcare; #L-003544) and hGLUD1/GDH1 (Dharmacon #L-004032). ON-TARGETplus non-targeting Pool (Dharmacon, GE Healthcare) or Allstar siRNA (Qiagen, Antwerp, Belgium) was used as negative controls.
Statistics
Data represent means ± s.e.m. All experiments were repeated at least three times independently, and sample size was chosen based on similar experiments in previous publications. S.e.m. are sometimes smaller than symbols. Similar variance is reflected by small s.e.m. with equal n between the different conditions of a same experiment. Outliers were identified using Grubb's test. Two-tailed unpaired Student's t-test, one-way analysis of variance (Bonferroni post-hoc test) and two-way analysis of variance were used where appropriate. Po 0.05 was considered to be statistically significant.
